MIRA News

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

Cycle Syncing® Method is Clinically Shown to Reduce PMS Symptoms for 92% of participants in 60 days

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

Form 8-K

Yılın Müslüman Dostu Oteli-The Mira Hong Kong, Miramar Travel ve Türkiye Konsolosluğu ile İkinci Yılında Kültürel Açıdan Zenginleştirici İftar Yemeğine Ev Sahipliği Yapıyor USA - Turkish USA - English

Women's Health Company Mira Calls for Federal Reform of U.S. Sex Education

MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study

Barjeel Geojit launches India Opportunities Fund

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain